B

BioXcel Therapeutics
D

BTAI

1.79000
USD
0.07
(4.07%)
مغلق
حجم التداول
4,901
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
10,840,322
أصول ذات صلة
A
ALLO
-0.01000
(-0.66%)
1.49500 USD
C
CRSP
-1.350
(-2.04%)
64.760 USD
E
EDIT
-0.11000
(-3.38%)
3.14000 USD
GILD
GILD
3.000
(2.65%)
116.210 USD
N
NTLA
0.830
(6.50%)
13.595 USD
PFE
PFE
-0.555
(-2.19%)
24.810 USD
REGN
REGN
-1.20
(-0.21%)
563.22 USD
S
SGMO
-0.01190
(-1.99%)
0.58600 USD
VRTX
VRTX
-2.89
(-0.61%)
469.58 USD
المزيد
الأخبار المقالات

العنوان: BioXcel Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.